CRISPR-Cas effector polypeptides and methods of use thereof
AssigneeThe Regents of the University of California
InventorsJennifer A. Doudna, Jillian F. Banfield, Basem Al-Shayeb
Life of this patent
Estimating the term…
Abstract
The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA.
Claims20
A composition comprising:
- a) a Cas12L polypeptide, or a nucleic acid molecule encoding the Cas12L polypeptide, wherein the Cas12L polypeptide comprises an amino acid sequence having 99% or more amino acid sequence identity with the amino acid sequence set forth in SEQ ID NO:
- 102;
- and
- b) a Cas12L guide RNA, or one or more DNA molecules encoding the Cas12L guide RNA, wherein the guide RNA is engineered such that the guide RNA's guide sequence is heterologous with the guide RNA's scaffold.
A method of modifying a target nucleic acid, the method comprising contacting the target nucleic acid with:
- a) a Cas12L polypeptide that comprises an amino acid sequence having 99% or more amino acid sequence identity with the amino acid sequence set forth in SEQ ID NO:
- 102;
- and
- b) a Cas12L guide RNA comprising a guide sequence that hybridizes to a target sequence of the target nucleic acid, wherein the guide RNA is engineered such that the guide RNA's guide sequence is heterologous with the guide RNA's scaffold,
- wherein said contacting results in modification of the target nucleic acid by the Cas12L polypeptide.
Dependencies are inferred from the claim text.